These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33125138)

  • 21. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
    Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
    Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paclitaxel in combination with cetuximab exerts antitumor effect by suppressing NF-κB activity in human oral squamous cell carcinoma cell lines.
    Harada K; Ferdous T; Kobayashi H; Ueyama Y
    Int J Oncol; 2014 Dec; 45(6):2439-45. PubMed ID: 25230791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exchanging human Fcgamma1 with murine Fcgamma2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model.
    Lutterbuese P; Brischwein K; Hofmeister R; Crommer S; Lorenczewski G; Petersen L; Lippold S; da Silva A; Locher M; Baeuerle PA; Schlereth B
    Cancer Immunol Immunother; 2007 Apr; 56(4):459-68. PubMed ID: 16937114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Defucosylated Mouse Anti-CD10 Monoclonal Antibody (31-mG
    Kawabata H; Suzuki H; Ohishi T; Kawada M; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2022 Apr; 41(2):59-66. PubMed ID: 35471051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with
    Ohishi T; Kato Y; Kaneko MK; Ohba SI; Inoue H; Harakawa A; Kawada M
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32839411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical characterization of a novel investigational monoclonal antibody CM313 with potent CD38-positive cell killing activity.
    Liu W; Yu J; Sun K; Song Q; Li Y; He Y; Wang Y; Xu G; Wang C; Chen B
    Front Immunol; 2024; 15():1410457. PubMed ID: 38765013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of the antibody immunotherapy by the anti-MUC1 monoclonal antibody to the oral squamous cell carcinoma in vitro.
    Shimizu M; Imai M
    Biol Pharm Bull; 2008 Dec; 31(12):2288-93. PubMed ID: 19043215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel anti-EGFR monoclonal antibody (EMab-17) exerts antitumor activity against oral squamous cell carcinomas via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
    Takei J; Kaneko MK; Ohishi T; Kawada M; Harada H; Kato Y
    Oncol Lett; 2020 Apr; 19(4):2809-2816. PubMed ID: 32218834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Defucosylated Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Exerted Antitumor Activities in Mouse Xenograft Models of Canine Mammary Gland Tumor.
    Tanaka T; Ohishi T; Saito M; Suzuki H; Kaneko MK; Kawada M; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2022 Jun; 41(3):142-149. PubMed ID: 35666554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a complete human anti-human transferrin receptor C antibody as a novel marker of oral dysplasia and oral cancer.
    Nagai K; Nakahata S; Shimosaki S; Tamura T; Kondo Y; Baba T; Taki T; Taniwaki M; Kurosawa G; Sudo Y; Okada S; Sakoda S; Morishita K
    Cancer Med; 2014 Aug; 3(4):1085-99. PubMed ID: 24890018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma.
    Shinriki S; Jono H; Ota K; Ueda M; Kudo M; Ota T; Oike Y; Endo M; Ibusuki M; Hiraki A; Nakayama H; Yoshitake Y; Shinohara M; Ando Y
    Clin Cancer Res; 2009 Sep; 15(17):5426-34. PubMed ID: 19706815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Fas Ligand (FasL)-Fused Humanized Antibody Against Tumor-Associated Glycoprotein 72 Selectively Exhibits the Cytotoxic Effect Against Oral Cancer Cells with a Low FasL/Fas Ratio.
    Chien MH; Chang WM; Lee WJ; Chang YC; Lai TC; Chan DV; Sharma R; Lin YF; Hsiao M
    Mol Cancer Ther; 2017 Jun; 16(6):1102-1113. PubMed ID: 28292939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).
    El-Sahwi K; Bellone S; Cocco E; Casagrande F; Bellone M; Abu-Khalaf M; Buza N; Tavassoli FA; Hui P; Rüttinger D; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Mol Cancer Ther; 2010 Jan; 9(1):57-66. PubMed ID: 20053761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer.
    Liao MY; Lai JK; Kuo MY; Lu RM; Lin CW; Cheng PC; Liang KH; Wu HC
    Oncotarget; 2015 Sep; 6(28):24947-68. PubMed ID: 26317650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor activities against breast cancers by an afucosylated anti-HER2 monoclonal antibody H
    Tanaka T; Suzuki H; Ohishi T; Kaneko MK; Kato Y
    Cancer Sci; 2024 Jan; 115(1):298-309. PubMed ID: 37942574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation of an anti-desmoglein 3 antibody without pathogenic activity of pemphigus vulgaris for therapeutic application to squamous cell carcinoma.
    Funahashi SI; Kawai S; Fujii E; Taniguchi K; Nakano K; Ishikawa S; Aburatani H; Suzuki M
    J Biochem; 2018 Dec; 164(6):471-481. PubMed ID: 30239818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a recombinant anti-VEGFR2-EPCAM bispecific antibody to improve antiangiogenic efficiency.
    Barzaman K; Samadi M; Moradi-Kalbolandi S; Majidzadeh-A K; Salehi M; Jalili N; Jazayeri MH; Khorammi S; Darvishi B; Siavashi V; Shekarabi M; Farahmand L
    Exp Cell Res; 2021 Aug; 405(2):112685. PubMed ID: 34090863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IMT030122, A novel engineered EpCAM/CD3/4-1BB tri-specific antibody, enhances T-cell recruitment and demonstrates anti-tumor activity in mouse models of colorectal cancer.
    Shen J; Qian N; Xu G; Dou X; An Y; Yang C; Liu Y; Liu Y; Pan X; Wang J; Bai G; Chen H; Zhu X; Gao X; Zhou G; Xu Q
    Int Immunopharmacol; 2024 Aug; 137():112424. PubMed ID: 38878486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of Core-Fucose-Deficient Humanized and Chimeric Anti-Human Podoplanin Antibodies.
    Kaneko MK; Ohishi T; Nakamura T; Inoue H; Takei J; Sano M; Asano T; Sayama Y; Hosono H; Suzuki H; Kawada M; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2020 Oct; 39(5):167-174. PubMed ID: 33085938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor Activities in Mouse Xenograft Models of Canine Mammary Gland Tumor by Defucosylated Mouse-Dog Chimeric Anti-Epidermal Growth Factor Receptor Antibody (E134Bf).
    Li G; Suzuki H; Takei J; Asano T; Sano M; Tanaka T; Harada H; Mizuno T; Ohishi T; Kawada M; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2022 Apr; 41(2):53-58. PubMed ID: 35471048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.